Statement Of Cash Flows [Abstract]

Marinomed Biotech AG - Filing #997033

Concept 2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
1,194 EUR
0 EUR
Adjustments to reconcile profit (loss) other than changes in working capital
484,000 EUR
1,630,000 EUR
Adjustments for decrease (increase) in trade and other receivables
1,521 EUR
7,848,000 EUR
Adjustments for increase (decrease) in trade and other payables
1,450 EUR
8,476,000 EUR
Adjustments for decrease (increase) in other assets
89,000 EUR
83,000 EUR
Finance costs paid, classified as operating activities
4,487,000 EUR
3,576,000 EUR
Finance income received, classified as operating activities
0 EUR
0 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from exercise of options
- EUR
3,041,000 EUR
Repayments of non-current borrowings
2,000,000 EUR
3,000,000 EUR
Proceeds from issue of bonds, notes and debentures
1,800 EUR
6,000,000 EUR
Payments for share issue costs
- EUR
8,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.